Regeneron Pharmaceuticals Inc (REGN)

Days of sales outstanding (DSO)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Receivables turnover		2.30	2.27	2.65	2.71	3.32
DSO	days	158.58	160.56	137.58	134.56	110.00

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.30
= 158.58

The Days Sales Outstanding (DSO) metric for Regeneron Pharmaceuticals, Inc. has varied over the past five years. In 2023, the DSO stands at 157.70 days, showing a slight decrease compared to the previous year where it was 159.78 days. This indicates that the company took approximately 157.70 days to collect its accounts receivable in 2023.

Looking back at historical performance, there was a significant decrease in DSO from 2021 to 2022, highlighting an improvement in the company's efficiency in collecting payments from customers. Conversely, in 2020, there was a notable increase in DSO, suggesting potential challenges in accounts receivable management during that period.

Overall, while the DSO has fluctuated over the years, a lower DSO typically indicates that the company is collecting payments more quickly, which can positively impact cash flow and liquidity. It is essential for Regeneron Pharmaceuticals, Inc. to monitor and manage its DSO effectively to ensure continued financial stability and operational efficiency.